LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) is investigating potential claims on behalf of investors of KaloBios Pharmaceuticals, Inc. (“KaloBios” or the “Company”) (NASDAQ: KBIO) concerning the Company’s and its officers’ possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured KaloBios investors.
On December 17, 2015, news outlets reported that Martin Shkreli, the CEO of KaloBios, was arrested on fraud charges relating to his illegal use of stock from Retrophin Inc. to pay off debts associated with other unrelated business ventures. On this news, KaloBios shares plummeted pre-market, and trading has since been halted.
If you purchased KaloBios securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.